AXSM
Axsome Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 129 | +8 | 27.56M | $6.74B | +16 | −9 |
| Q1 2026 | 125 | +4 | 27.78M | $4.69B | +9 | −6 |
| Q4 2025 | 120 | +1 | 28.15M | $5.13B | +2 | — |
| Q3 2025 | 19 | 0 | 15.93M | $1.93B | +1 | −2 |
| Q2 2025 | 17 | -1 | 13.98M | $1.46B | — | −1 |
| Q1 2025 | 15 | +3 | 4.41M | $513.88M | +3 | — |
| Q4 2024 | 12 | +1 | 3.90M | $329.80M | +1 | — |
| Q3 2024 | 10 | 0 | 3.50M | $314.34M | — | — |
| Q2 2024 | 10 | — | 4.77M | $384.18M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 884.89K | — | $71.25M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Citadel Advisors ✦ | 753.24K | — | $60.64M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 3 | Millennium Management ✦ | 739.82K | — | $59.56M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 734.62K | — | $59.14M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 5 | Adage Capital Partners ✦ | 730.00K | — | $58.77M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 479.04K | — | $38.56M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 404.22K | — | $32.54M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 27.18K | — | $2.19M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 12.84K | — | $1.03M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | D. E. Shaw & Co. ✦ | 6.33K | — | $509,887 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 408 holders, 37.64M shares, $6.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 10.00K sh · $2.09M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology